|
1.
|
Barth BM, Shanmugavelandy SS, Kaiser JM, McGovern C, Altinoglu EI, Haakenson JK, Hengst JA, Gilius EL, Knupp SA, Fox TE, Smith JP, Ritty TM, Adair JH, Kester M. PhotoImmunoNanoTherapy Reveals an Anticancer Role for Sphingosine Kinase 2 and Dihydrosphingosine-1-Phosphate. ACS Nano. 2013 Mar 26; 7(3):2132-44.
|
|
|
|
|
2.
|
Hengst JA, Yun JK. Sphingosine kinase: a key to solving the 'French Paradox'? Br J Pharmacol. 2012 Jul; 166(5):1603-4.
|
|
|
|
|
3.
|
Madhunapantula SV, Hengst J, Gowda R, Fox TE, Yun JK, Robertson GP. Targeting sphingosine kinase-1 to inhibit melanoma. Pigment Cell Melanoma Res. 2012 Mar; 25(2):259-74.
|
|
|
|
|
4.
|
Ali-Rahmani F, Hengst JA, Connor JR, Schengrund CL. Effect of HFE variants on sphingolipid expression by SH-SY5Y human neuroblastoma cells. Neurochem Res. 2011 Sep; 36(9):1687-96.
|
|
|
|
|
5.
|
Hengst JA, Wang X, Sk UH, Sharma AK, Amin S, Yun JK. Development of a sphingosine kinase 1 specific small-molecule inhibitor. Bioorg Med Chem Lett. 2010 Dec 15; 20(24):7498-502.
|
|
|
|
|
6.
|
Karelia N, Desai D, Hengst JA, Amin S, Rudrabhatla SV, Yun J. Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells. Bioorg Med Chem Lett. 2010 Nov 15; 20(22):6816-9.
|
|
|
|
|
7.
|
Sharma AK, Sk UH, Gimbor MA, Hengst JA, Wang X, Yun J, Amin S. Synthesis and bioactivity of sphingosine kinase inhibitors and their novel aspirinyl conjugated analogs. Eur J Med Chem. 2010 Sep; 45(9):4149-56.
|
|
|
|
|
8.
|
Hengst JA, Guilford JM, Conroy EJ, Wang X, Yun JK. Enhancement of sphingosine kinase 1 catalytic activity by deletion of 21 amino acids from the COOH-terminus. Arch Biochem Biophys. 2010 Feb 1; 494(1):23-31.
|
|
|
|
|
9.
|
Hengst JA, Guilford JM, Fox TE, Wang X, Conroy EJ, Yun JK. Sphingosine kinase 1 localized to the plasma membrane lipid raft microdomain overcomes serum deprivation induced growth inhibition. Arch Biochem Biophys. 2009 Dec; 492(1-2):62-73.
|
|
|
|
|
10.
|
Bayerl MG, Bruggeman RD, Conroy EJ, Hengst JA, King TS, Jimenez M, Claxton DF, Yun JK. Sphingosine kinase 1 protein and mRNA are overexpressed in non-Hodgkin lymphomas and are attractive targets for novel pharmacological interventions. Leuk Lymphoma. 2008 May; 49(5):948-54.
|
|
|
|
|
11.
|
Itagaki K, Yun JK, Hengst JA, Yatani A, Hauser CJ, Spolarics Z, Deitch EA. Sphingosine 1-phosphate has dual functions in the regulation of endothelial cell permeability and Ca2+ metabolism. J Pharmacol Exp Ther. 2007 Oct; 323(1):186-91.
|
|
|
|
|
12.
|
Francy JM, Nag A, Conroy EJ, Hengst JA, Yun JK. Sphingosine kinase 1 expression is regulated by signaling through PI3K, AKT2, and mTOR in human coronary artery smooth muscle cells. Biochim Biophys Acta. 2007 Apr; 1769(4):253-65.
|
|
|
|
|
13.
|
Hengst JA, Bond JS. Transport of meprin subunits through the secretory pathway: role of the transmembrane and cytoplasmic domains and oligomerization. J Biol Chem. 2004 Aug 13; 279(33):34856-64.
|
|
|
|
|
14.
|
Bertenshaw GP, Villa JP, Hengst JA, Bond JS. Probing the active sites and mechanisms of rat metalloproteases meprin A and B. Biol Chem. 2002 Jul-Aug; 383(7-8):1175-83.
|
|
|
|
|
15.
|
Tsukuba T, Kadowaki T, Hengst JA, Bond JS. Chaperone interactions of the metalloproteinase meprin A in the secretory or proteasomal-degradative pathway. Arch Biochem Biophys. 2002 Jan 15; 397(2):191-8.
|
|
|
|
|
16.
|
Hengst JA, Georgoff I, Isom HC, Jacob ST. Association of newly synthesized poly(A) polymerase with four distinct polypeptides. J Biol Chem. 1988 Dec 25; 263(36):19270-3.
|
|
|
|